China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294

Watchlist Manager
China Resources Boya Bio pharmaceutical Group Co Ltd Logo
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
Watchlist
Price: 30.96 CNY 0.23%
Market Cap: 15.6B CNY
Have any thoughts about
China Resources Boya Bio pharmaceutical Group Co Ltd?
Write Note

China Resources Boya Bio pharmaceutical Group Co Ltd
Intangible Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

China Resources Boya Bio pharmaceutical Group Co Ltd
Intangible Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Intangible Assets CAGR 3Y CAGR 5Y CAGR 10Y
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
Intangible Assets
ÂĄ328.4m
CAGR 3-Years
-1%
CAGR 5-Years
4%
CAGR 10-Years
27%
Beigene Ltd
HKEX:6160
Intangible Assets
ÂĄ982.3m
CAGR 3-Years
41%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Intangible Assets
ÂĄ8.5m
CAGR 3-Years
90%
CAGR 5-Years
112%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Intangible Assets
ÂĄ642.7m
CAGR 3-Years
40%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Intangible Assets
ÂĄ227.3m
CAGR 3-Years
11%
CAGR 5-Years
4%
CAGR 10-Years
8%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Intangible Assets
ÂĄ1.4B
CAGR 3-Years
4%
CAGR 5-Years
27%
CAGR 10-Years
18%
No Stocks Found

China Resources Boya Bio pharmaceutical Group Co Ltd
Glance View

Market Cap
15.6B CNY
Industry
Biotechnology

Boya Bio-pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of blood products. The company is headquartered in Fuzhou, Jiangxi and currently employs 1,652 full-time employees. The company went IPO on 2012-03-08. The firm's main products include human albumin, freeze-drying intravenous injection human immune globulin, human immune globulin, hepatitis B human immune globulin, hydrophobia human immune globulin, human fibrinogen, metformin hydrochloride, calcium dobesilate capsules, glimepiride and pioglitazone hydrochloride dispersible tablets, among others. The firm's blood products are mainly used in the treatment of tumor, liver diseases and diabetes, among others. The firm also provides diabetic pharmaceuticals and biochemical pharmaceuticals. The firm distributes its products mainly in domestic market.

Intrinsic Value
32.53 CNY
Undervaluation 5%
Intrinsic Value
Price

See Also

What is China Resources Boya Bio pharmaceutical Group Co Ltd's Intangible Assets?
Intangible Assets
328.4m CNY

Based on the financial report for Sep 30, 2024, China Resources Boya Bio pharmaceutical Group Co Ltd's Intangible Assets amounts to 328.4m CNY.

What is China Resources Boya Bio pharmaceutical Group Co Ltd's Intangible Assets growth rate?
Intangible Assets CAGR 10Y
27%

Over the last year, the Intangible Assets growth was -11%. The average annual Intangible Assets growth rates for China Resources Boya Bio pharmaceutical Group Co Ltd have been -1% over the past three years , 4% over the past five years , and 27% over the past ten years .

Back to Top